A randomized trial comparing ticlopidine hydrochloride with indobufen for the prevention of stroke in high-risk patients (tiss study)

Functional Neurology

Volumn 12, Issue 1, 1997, Pages 33-43

  Bergamasco, Bruno ^a   Benna, Paolo ^a   Carolei, Antonio ^b   Rasura, Maurizia ^c   Rudelli, Giuseppina ^d   Fieschi, Cesare ^c  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d Sanofi Winthrop Spa   (Italy)

Author keywords

antiplatelet drugs; indobufen; prevention; stroke; ticlopidine; transient ischemic attack

Indexed keywords

ANTITHROMBOCYTIC AGENT; INDOBUFEN; TICLOPIDINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; RASH; STOMACH HEMORRHAGE; STROKE; URTICARIA;

ADULT; AGED; CEREBROVASCULAR DISORDERS; FEMALE; HUMANS; MALE; MIDDLE AGED; PHENYLBUTYRATES; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; SURVIVAL ANALYSIS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 0031008252     PISSN: 03935264     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Dyken ML, Wolf PA, Barnett HJM et al. Risk factors in stroke. A statement for physicians by subcommittee on risk factors and stroke of the Stroke Council. Stroke 1984; 15:1105-1111
2. Hankey GJ, Slattery JM, Warlow CP. The prognosis of hospital-referred transient ischaemic attacks. J Neurol Neurosurg Psychiatry 1991;54:793-802
3. Antiplatelet Trialists' Collaboration: Secondary prevention of vascular events by prolonged antiplatelet therapy. BMJ 1988; 296:320-331
4. Antiplatelet Trialists' Collaboration: Collaborative overview of randomized trials of antiplatelet therapy - I: Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308:81-106
5. Gent M, Blakely JA, Easton JD, Ellis DJ, Sicurella J, Turpie AGG and the CATS group. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989; i: 1215-1220
6. Hass WK, Easton JD, Adams HP et al. for the Ticlopidine Aspirin Stroke Study Group. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989;321:501-507
7. Lavezzani M, Milanesi G, Sacchetti G, Pamparana F. Indobufen: results of a postmarketing surveillance study on 5642 cases. Current Therapy Research 1989;45:19-27
8. De Caterina R, Sicari R, Yan A et al. The deniantiomer form of indobufen totally accounts for the anti-cyclooxygenase and antiplatelet activity ex-vivo and for the increase in bleeding time by indobufen in man. Thromb Haemost 1992;67:258-263
9. Belcaro G, Pierangeli A, De Simone P. Long-term evaluation of the safety and efficacy of indobufen in cerebrovascular disease. Current Therapy Research 1990; 47:444-451
10. Rogan J and Multicentre Ischaemic Attack Study Group. Indobufen in secondary prevention of transient ischaemic attack. J Int Med Res 1990;18:240-244
11. Lachin JM, Foulkes MA. Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. Biometrics 1986; 42:507-516
12. Pocock SJ. Clinical Trials. A practical approach. Chichester; John Wiley & Sons 1983.
13. Harbison JW, for the Ticlopidine Aspirin Stroke Study Group. Ticlopidine versus aspirin for the prevention of recurrent stroke. Analysis of patients with minor stroke from the Ticlopidine Aspirin Stroke Study. Stroke 1992;23:1723-1727
14. Bellotti P, Claudiani F, Chiarella F et al. Left ventricular thrombi: changes in size and in platelet deposition during treatment with indobufen and ticlopidine. Cardiology 1990;77:272-279
15. Pratesi C, Pulli R, Milanesi G, Lavezzari M, Pamparana F, Bertini D. Indobufen versus placebo in the prevention of restenosis after carotid endarterectomy. A double-blind pilot study. J Int Med Res 1991;19:202-209
16. Saltiel E, Ward A. Ticlopidine: a review of its pharmacodynamic and pharmakinetic properties and therapeutic efficacy in platelet-dependent disease states. Drugs 1987; 34:222-262.
17. Stein B, Fuster V, Israel DH et al. Platelet inhibitor agents in cardiovascular disease: an update. J Am Coll Cardiol 1989;14:813-836
18. UK-TIA Study group. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991;54:1044-1054
19. Carolei A, Candelise L, Fiorelli M, Francucci BM, Motolese M, Fieschi C and the National Research Council and Rome Study Groups: Long-term prognosis of transient ischemic attacks and reversible ischemic neurologic deficits: a hospital-based study. Cerebrovascular Disorders 1992;2:266-272